600056 中国医药
2025/06 - 中期
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入17,075,860-6.71%34,148,36038,824,43137,592,65036,234,415
减:营业总成本16,438,280-6.80%32,983,44537,501,89536,137,94034,480,964
    其中:营业成本15,294,246-6.22%30,489,59434,440,81432,845,78631,018,239
               财务费用(9,775)-110.07%195,924112,038138,317221,691
               资产减值损失266-78.17%(175,326)(13,539)(280,660)(575,297)
公允价值变动收益5,891-631.44%127,4679851,922(2,135)
投资收益9,457324.46%(65,017)(15,792)51,00143,657
    其中:对联营企业和合营企业的投资收益28,74624.18%18,73677,04393,219113,900
营业利润524,870-16.59%931,5681,672,3341,199,698937,135
利润总额520,722-16.90%953,1891,640,5561,196,127940,106
减:所得税费用145,395-3.93%266,565398,435307,699225,830
净利润375,327-21.03%686,6241,242,120888,428714,276
减:非控股权益81,368-34.65%151,156194,081152,82767,219
股东净利润293,959-16.19%535,4681,048,039735,601647,057

市场价值指针
每股收益 (元) *0.197-16.20%0.3580.7010.4920.433
每股派息 (元) *0.020-9.57%0.1070.2100.1480.182
每股净资产 (元) *7.8371.33%7.9027.7287.230--
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容